Suven Pharmaceuticals Limited (NSE: SUVENPHAR)

Suven Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	368.2	472.31	648.03	445.64	71.82	116.95
Short-Term Investments	6,191	-	-	-	-	-
Trading Asset Securities	-	7,739	4,189	4,812	1,806	306.73
Cash & Short-Term Investments	6,559	8,211	4,837	5,258	1,878	423.69
Cash Growth	-8.10%	69.75%	-8.00%	180.01%	343.20%	113.55%
Accounts Receivable	1,840	1,337	1,109	2,364	1,024	1,172
Other Receivables	117.7	562.28	665.92	480.04	516.22	358.79
Receivables	1,974	1,907	1,777	2,846	1,542	1,533
Inventory	2,155	2,326	3,306	3,000	2,127	1,863
Prepaid Expenses	-	49.21	86.28	64	43.97	38.59
Other Current Assets	988.7	138.34	103.79	111.67	56.72	58.28
Total Current Assets	11,677	12,632	10,110	11,279	5,648	3,916
Property, Plant & Equipment	8,928	7,868	7,662	5,620	5,349	4,555
Long-Term Investments	1,321	1,306	1,171	1,171	3,612	3,075
Goodwill	2,138	602.58	602.58	-	-	-
Other Intangible Assets	577.8	16.67	19.32	22.36	25.91	29.4
Other Long-Term Assets	340.8	116.09	91.64	203.02	109.54	151.99
Total Assets	25,056	22,541	19,657	18,296	14,745	11,728
Accounts Payable	652.8	423.57	700.92	1,059	829.31	710.56
Accrued Expenses	171.3	151.87	128.17	266	198.03	136.07
Short-Term Debt	19.3	385.75	445.98	-	641.89	520.38
Current Portion of Long-Term Debt	-	-	200	671.33	414.48	420
Current Portion of Leases	68.7	51.86	4.79	10.91	10.68	4.04
Current Income Taxes Payable	128.2	-	2.94	36.42	-	52.54
Current Unearned Revenue	-	6.89	8.08	-	-	-
Other Current Liabilities	1,341	49.02	96.79	59.27	103.08	160.17
Total Current Liabilities	2,381	1,069	1,588	2,103	2,197	2,004
Long-Term Debt	71.4	-	45.64	284.4	355.91	912.53
Long-Term Leases	235.2	212.36	7	4.63	7.39	5.12
Long-Term Deferred Tax Liabilities	859.3	647.91	582.35	543.15	309.33	275.97
Other Long-Term Liabilities	1,224	97.68	82.95	77.85	44.99	40.86
Total Liabilities	4,771	2,034	2,306	3,024	2,937	3,281
Common Stock	254.6	254.57	254.57	254.57	254.57	127.28
Additional Paid-In Capital	-	1,096	1,096	1,096	1,096	1,223
Retained Earnings	-	18,894	15,894	13,820	10,308	6,947
Comprehensive Income & Other	19,529	262.39	107.17	101.65	150.09	150.11
Shareholders' Equity	20,284	20,507	17,352	15,272	11,808	8,448
Total Liabilities & Equity	25,056	22,541	19,657	18,296	14,745	11,728
Total Debt	394.6	649.96	703.41	971.27	1,430	1,862
Net Cash (Debt)	6,164	7,561	4,134	4,287	447.4	-1,438
Net Cash Growth	-7.01%	82.91%	-3.56%	858.10%	-	-
Net Cash Per Share	24.18	29.70	16.24	16.84	1.76	-5.65
Filing Date Shares Outstanding	254.52	254.56	254.56	254.56	254.56	254.56
Total Common Shares Outstanding	254.52	254.56	254.56	254.56	254.56	254.56
Working Capital	9,295	11,563	8,523	9,176	3,450	1,913
Book Value Per Share	77.73	80.56	68.16	59.99	46.39	33.18
Tangible Book Value	17,068	19,887	16,730	15,249	11,782	8,418
Tangible Book Value Per Share	67.06	78.12	65.72	59.90	46.28	33.07
Land	-	150.46	150.46	150.46	150.46	150.46
Buildings	-	2,209	2,200	1,813	1,411	1,226
Machinery	-	5,607	5,410	4,750	3,909	2,990
Construction In Progress	-	1,790	1,651	299.94	961.49	1,016
Leasehold Improvements	-	42.6	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.